We provide targeted LC-MS bioanalysis for a wide range of therapeutic modalities. Whether you’re working with small molecules, proteins or therapeutic peptides, our team develops approaches tailored to your analyte’s properties, matrix and study requirements.
From discovery through regulated studies, we provide high-sensitivity LC-MS/MS analysis optimized for small molecules. Our workflows are designed to support efficient timelines while delivering reliable, reproducible data for confident decision-making.
Key strengths include:
Veloxity offers targeted support for protein-based therapeutics, including mAbs, ADCs and nanobodies. Our team develops and validates customized LC-MS workflows to meet the sensitivity, specificity and applicable regulatory needs of each program.
Our experience includes:
What matters most:
Veloxity develops peptide-focused methods with the next development stage in mind, supporting continuity from fit-for-purpose work through GLP and clinical bioanalysis.
Peptides present distinct challenges in sensitivity, selectivity, stability and sample preparation. Veloxity provides peptide-specific method development, fit-for-purpose qualification or validation and support for preclinical and clinical bioanalysis.
Capabilities include:
Depending on the analyte and study requirements, LC-MS can offer important advantages for peptide bioanalysis:
We also support non-traditional and exploratory modalities that require customized bioanalytical approaches. When a program doesn’t fit a standard workflow, our scientists adapt method development and analysis to the molecule, matrix and study objectives.
Explore a novel LC-MS/MS workflow for monoclonal antibody-based therapeutics designed to improve specificity, sensitivity and method performance. Download the report to learn how the approach can support more efficient bioanalysis of human IgG-based therapeutics.
Talk with our scientists about the molecule, matrix, sensitivity requirements and development stage for your program.
